Mesoblast (MESO) Free Cash Flow Growth (1y) (2017 - 2023)
Mesoblast (MESO) Free Cash Flow Growth (1y) (2017 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Mesoblast | 18.89 Bn | 18.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -18.70% |
| Mar 31, 2023 | -4.71% |
| Dec 31, 2022 | 9.69% |
| Sep 30, 2022 | 21.50% |
| Jun 30, 2022 | 26.56% |
| Mar 31, 2022 | 36.58% |
| Dec 31, 2021 | 40.42% |
| Sep 30, 2021 | 35.39% |
| Jun 30, 2021 | -38.76% |
| Mar 31, 2021 | -23.00% |
| Dec 31, 2020 | -2,199.25% |
| Sep 30, 2020 | -81.05% |
| Jun 30, 2020 | 28.56% |
| Mar 31, 2020 | 6.11% |
| Dec 31, 2019 | -165.55% |
| Sep 30, 2019 | 20.40% |
| Jun 30, 2019 | 5.46% |
| Mar 31, 2019 | -8.09% |
| Dec 31, 2018 | 113.65% |
| Sep 30, 2018 | 3.99% |